» Articles » PMID: 20583203

Hospitalization Costs Associated with Warfarin-related Bleeding Events Among Older Community-dwelling Adults

Overview
Publisher Wiley
Date 2010 Jun 29
PMID 20583203
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: A prior paper from this study demonstrated that patient report of receiving medication instructions from health care professionals is associated with reduced risk of warfarin-related bleeding hospitalizations. The objective of this analysis was to describe the hospitalization costs due to warfarin-related bleeding events in older community-dwelling adults and to estimate the hospitalization costs avoided due to the receipt of medication instruction from different sources.

Methods: We estimated the expected hospitalization costs associated with four instruction sources based on the respective incidence rate of observed hospitalizations and mean hospitalization cost for warfarin-related bleeding episodes from a prospective cohort study of beneficiaries of the Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE). We estimated hospitalization costs avoided due to each instruction source compared to no instructions using the payer's perspective. We conducted probabilistic sensitivity analysis to account for uncertainty in our parameters.

Results: One hundred twenty-six warfarin-related bleeding hospitalizations occurred during the observation period with a mean cost of $10,819 (SD: $11,536). The mean expected hospitalization cost from a warfarin-related bleeding hospitalization without instruction was $835 per year per person. Hospitalization costs avoided with instruction from a health care professional ranged from $443 to $481 per year per person.

Conclusions: The costs per hospitalization associated with warfarin-related bleeding events are substantial. Instructions for warfarin management from a health care professional may reduce the number of warfarin-related bleeding hospitalizations and associated costs. Investments in interventions to improve communication regarding warfarin management may be justified economically based on the potential cost savings estimated in this study.

Citing Articles

Community-Based Pharmacist Anticoagulation Clinic Outcomes Compared with Physician Management.

Kurochka I, Jadallah J, Nadpara P, Goode J Innov Pharm. 2024; 15(1).

PMID: 38779104 PMC: 11107966. DOI: 10.24926/iip.v15i1.5929.


Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada.

Hafeez A, Cipriano L, Kim R, Zaric G, Schwarz U, Sarma S Pharmacoeconomics. 2023; 42(1):69-90.

PMID: 37596504 DOI: 10.1007/s40273-023-01309-z.


Impact of adherence to warfarin therapy during 12 weeks of pharmaceutical care in patients with poor time in the therapeutic range.

Marcatto L, Boer B, Sacilotto L, Olivetti N, Darrieux F, Scanavacca M J Thromb Thrombolysis. 2020; 51(4):1043-1049.

PMID: 32974757 DOI: 10.1007/s11239-020-02280-8.


Pharmacists' influence on adverse reactions to warfarin: a randomised controlled trial in elderly rural patients.

Falamic S, Lucijanic M, Ortner-Hadziabdic M, Marusic S, Bacic-Vrca V Int J Clin Pharm. 2019; 41(5):1166-1173.

PMID: 31493209 DOI: 10.1007/s11096-019-00894-4.


Impact of an electronic medium delivery of warfarin education in a low income, minority outpatient population: a pilot intervention study.

Heinrich K, Sanchez K, Hui C, Talabi K, Perry M, Qin H BMC Public Health. 2019; 19(1):1050.

PMID: 31382942 PMC: 6683532. DOI: 10.1186/s12889-019-7370-4.